- Raw materials
- Cephalosporins
- Cefmetazole
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Cefmetazole API Manufacturers & Suppliers
6 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Cefmetazole | CAS No: 56796-20-4 | GMP-certified suppliers
A medication that treats infections caused by susceptible bacteria with broad-spectrum antibacterial activity, primarily targeting systemic infections in hospital and clinical settings.
Therapeutic categories
Primary indications
- For the treatment of infections caused by susceptible organisms
Product Snapshot
- Cefmetazole is formulated as an injectable small molecule antibiotic in powder form for solution
- It is primarily indicated for treating infections caused by susceptible organisms
- The product has both approved and investigational regulatory statuses
Clinical Overview
Pharmacologically, cefmetazole functions by inhibiting bacterial cell wall synthesis. It binds with high affinity to penicillin-binding proteins (PBPs), thereby disrupting the cross-linking of peptidoglycan chains essential for bacterial cell wall integrity. This mechanism results in a bactericidal effect similar to that of penicillins and other beta-lactam antibiotics. Compared to first-generation cephalosporins, cefmetazole offers enhanced activity against indole-positive Proteus species, Serratia species, anaerobic gram-negative bacilli such as Bacteroides fragilis, and certain strains of Escherichia coli, Klebsiella, and Proteus mirabilis. However, it is less potent than cefoxitin or cefotetan against most gram-negative bacilli.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for cefmetazole include adequate systemic bioavailability after parenteral administration and renal excretion as the primary elimination route. The drug’s pharmacokinetics may require dose adjustment in patients with impaired renal function to avoid accumulation and potential toxicity.
Safety considerations include monitoring for adverse events common to beta-lactam antibiotics. Although no severe side effects have been prevalently documented, cefmetazole possesses inherent nephrotoxic potential, necessitating caution in patients with preexisting renal impairment. Allergic reactions may also occur in individuals sensitive to beta-lactam antibiotics.
Cefmetazole is approved for clinical use in various markets, often under generic names or within regional formularies. It is utilized in hospital and clinical settings for systemic antibacterial therapy.
From an API sourcing perspective, quality considerations include verifying compliance with relevant pharmacopeial standards and ensuring impurity profiles are within specified limits. Due to its beta-lactam structure and sulfur-containing moiety, controlled storage conditions to prevent degradation are essential. Procurement should be aligned with robust supply chain validation to maintain consistent quality for pharmaceutical formulation.
Identification & chemistry
| Generic name | Cefmetazole |
|---|---|
| Molecule type | Small molecule |
| CAS | 56796-20-4 |
| UNII | 3J962UJT8H |
| DrugBank ID | DB00274 |
Pharmacology
| Summary | Cefmetazole is a second-generation cephalosporin antibiotic that exerts bactericidal effects by inhibiting bacterial cell wall synthesis through high affinity binding to multiple penicillin-binding proteins (PBPs). It exhibits activity against a broad spectrum of gram-positive and gram-negative organisms, including indole-positive Proteus, Serratia, anaerobic gram-negative bacilli, and select strains of E. coli, Klebsiella, and P. mirabilis. Its pharmacodynamic profile targets key enzymes involved in peptidoglycan cross-linking, disrupting cell wall integrity and leading to bacterial cell death. |
|---|---|
| Mechanism of action | The bactericidal activity of cefmetazole results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). |
| Pharmacodynamics | Cefmetazole is a second-generation cephalosporin. The cephalosporins are bactericidal drugs with both gram-positive and gram-negative activity. They inhibit bacterial cell wall synthesis in a way similar to the penicillins. Cefmetazole is more active than 1st-generation cephalosporins against indole-positive <i>Proteus</i>, <i>Serratia</i>, anaerobic gram-negative bacilli (including <i>B. fragilis</i>), and some <i>E. coli</i>, <i>Klebsiella</i>, and <i>P. mirabilis</i>, but is less active than cefoxitin or cefotetan against most gram-negative bacilli. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Penicillin binding protein 2a | Staphylococcus aureus | inhibitor |
| Penicillin-binding protein 1A | Escherichia coli (strain K12) | inhibitor |
| Penicillin-binding protein 1B | Escherichia coli (strain K12) | inhibitor |
ADME / PK
| Absorption | Bioavailability is approximately 100% following intramuscular injection. |
|---|---|
| Half-life | 1.50 ±0.14 hours |
| Metabolism | No appreciable metabolism. |
Formulation & handling
- Cefmetazole is a small molecule antibiotic formulated exclusively for parenteral administration via intramuscular or intravenous injection.
- The compound exhibits moderate water solubility, facilitating its preparation as a powder for solution in injectable dosage forms.
- Handling should consider its classification as an n-acyl-alpha amino acid derivative, with no noted sensitivity to food affecting formulation stability.
Regulatory status
Supply Chain
| Supply chain summary | Cefmetazole is manufactured by originator companies including Pharmacia and Upjohn Co. The branded product has a presence in the US, EU, and other global markets. Patent expiry has led to existing generic competition in multiple regions. |
|---|
Safety
| Toxicity | Oral LD<sub>50</sub> in rats is 3,204 mg/kg. With other b-lactam antibiotics, adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. |
|---|
- Oral LD50 in rats is 3,204 mg/kg, indicating moderate acute toxicity
- Overdosage with β-lactam antibiotics may result in gastrointestinal distress and neurological effects such as convulsions
- Handle with appropriate protective equipment to minimize exposure risk
Cefmetazole is a type of Cephalosporins
Cephalosporins are a class of pharmaceutical active ingredients (APIs) widely used in the field of antibiotics. They belong to the beta-lactam family, which also includes penicillins. Cephalosporins are derived from a fungus called Acremonium cephalosporium and are known for their potent antimicrobial properties.
These APIs are commonly used to treat a wide range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and even meningitis. Cephalosporins work by inhibiting the synthesis of bacterial cell walls, leading to the disruption of bacterial growth and ultimately their destruction.
Cephalosporins are classified into generations based on their antimicrobial spectrum and activity against specific bacteria. The first-generation cephalosporins are effective against Gram-positive bacteria, while subsequent generations show broader activity against both Gram-positive and Gram-negative bacteria.
Pharmaceutical companies manufacture cephalosporins in various formulations, including tablets, capsules, injectable solutions, and suspensions. They are often prescribed by healthcare professionals and are available under different brand names in the market.
It is important to note that like other antibiotics, cephalosporins should be used judiciously to prevent the development of antibiotic resistance. Proper dosage and adherence to treatment guidelines are crucial to maximize their effectiveness and minimize the risk of resistance.
In conclusion, cephalosporins are a vital category of APIs widely used in the treatment of bacterial infections. Their broad spectrum of activity and effectiveness make them an essential tool in modern medicine.
Cefmetazole API manufacturers & distributors
Compare qualified Cefmetazole API suppliers worldwide. We currently have 6 companies offering Cefmetazole API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Amicogen | Producer | China | China | CoA, JDMF | 3 products |
| Farmabios | Producer | Italy | Italy | CoA, GMP | 58 products |
| Fujian Fukang Pharma | Producer | China | China | CoA, JDMF, WC | 4 products |
| Jeil Pharmaceutical | Producer | South Korea | South Korea | CoA, JDMF | 12 products |
| JW Pharmaceutical | Producer | South Korea | South Korea | CoA, JDMF | 7 products |
| Yungjin Pharmaceutical | Producer | South Korea | South Korea | CoA, JDMF | 10 products |
When sending a request, specify which Cefmetazole API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Cefmetazole API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
